Johnson & Johnson (JNJ) Peer Comparison
$266.17
$-4.39
(-1.62%)
As on 03-Nov-2026 16:25EST
Market cap
$662,492 Mln
Revenue (TTM)
$99,335 Mln
P/E Ratio
41.8
P/B Ratio
8
Div. Yield
2 %
Edit
| Johnson & Johnson (JNJ) | Eli Lilly and Company (LLY) | Merck & Company Inc (MRK) | Novartis AG - ADR | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
662,492 | 1,262,667 | 361,021 | 304,257 | 211,814 |
Revenue ($ Mln) |
99,335 | 86,462 | 67,302 | 56,306 | 30,987 |
Net Profit ($ Mln) |
16,095.00 | 27,579.70 | 2,453.00 | 10,033.05 | -3,863.00 |
Net Margin (%) |
16.20 | 31.90 | 3.64 | 17.82 | -12.47 |
RoE (%) |
19.78 | 77.18 | 10.72 | 26.54 | -21.14 |
Price to Earnings |
41.76 | 46.11 | 116.13 | 30.74 | 17.74 |
Price-To-Book |
8.00 | 31.35 | 8.29 | 7.92 | 16.24 |
Income Statement ($ Mln)
| Johnson & Johnson (JNJ) | Eli Lilly and Company (LLY) | Merck & Company Inc (MRK) | Novartis AG - ADR | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
99,335.00 | 86,462.00 | 67,302.00 | 56,305.86 | 30,987.00 |
|
Cost of Revenue
|
30,982.00 | 14,149.70 | 15,512.00 | 14,289.25 | 6,219.00 |
|
Gross Profit
|
63,937.00 | 54,127.00 | 46,731.00 | 41,121.51 | 23,208.00 |
|
Operating Expenses
|
42,828.00 | 32,481.90 | 40,863.00 | 27,682.63 | 26,126.00 |
|
Operating Profit (EBIT)
|
25,525.00 | 39,830.40 | 10,927.00 | 14,333.98 | -1,252.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
17,737.00 | 34,769.20 | 4,762.00 | 12,645.68 | -2,533.00 |
|
Provision for Tax
|
1,642.00 | 7,189.50 | 2,313.00 | 2,630.63 | 1,330.00 |
|
Profit after Tax (Net Income)
|
16,095.00 | 27,579.70 | 2,453.00 | 10,033.05 | -3,863.00 |
|
Minority Interest
|
0.00 | 0.00 | 6.00 | 18.00 | 0.00 |
|
Consolidated Profit
|
5,116.00 | 6,636.00 | 2,963.00 | 2,409.00 | 0.00 |
Liabilities ($ Mln)
| Johnson & Johnson (JNJ) | Eli Lilly and Company (LLY) | Merck & Company Inc (MRK) | Novartis AG - ADR | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
81,529.00 | 40,271.00 | 0.00 | 37,228.00 | 13,038.00 |
|
Minority Interest
|
0.00 | 0.00 | 6.00 | 18.00 | 0.00 |
|
Non-Current Liabilities
|
60,439.00 | 60,805.00 | 0.00 | 47,060.00 | 26,450.00 |
|
Current Liabilities
|
55,457.00 | 46,996.00 | 0.00 | 32,525.00 | 12,002.00 |
|
Total Liabilities
|
199,210.00 | 112,476.00 | 136,866.00 | 115,569.20 | 59,023.00 |
Assets ($ Mln)
| Johnson & Johnson (JNJ) | Eli Lilly and Company (LLY) | Merck & Company Inc (MRK) | Novartis AG - ADR | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
141,074.00 | 82,809.00 | 0.00 | 88,402.00 | 34,855.00 |
|
Current Assets
|
56,351.00 | 65,263.00 | 0.00 | 28,747.00 | 16,554.00 |
|
Total Assets
|
199,210.00 | 112,476.00 | 136,866.00 | 115,569.20 | 59,023.00 |
|
Total Debt*
|
44,651.00 | 49,503.00 | 0.00 | 48,310.00 | 26,231.00 |
|
Net Current Assets
|
894.00 | 18,267.00 | 0.00 | -3,778.00 | 0.00 |
Cashflow ($ Mln)
| Johnson & Johnson (JNJ) | Eli Lilly and Company (LLY) | Merck & Company Inc (MRK) | Novartis AG - ADR | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
24,530.00 | 16,813.00 | 16,472.00 | 19,242.03 | 10,019.00 |
|
Cash Flow from Investing Activities
|
-23,588.00 | -10,972.00 | -13,741.00 | -4,901.98 | -4,793.00 |
|
Cash from Financing Activities
|
-5,539.00 | -2,213.00 | -1,922.00 | -14,943.13 | -7,745.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Johnson & Johnson (JNJ) | Eli Lilly and Company (LLY) | Merck & Company Inc (MRK) | Novartis AG - ADR | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
22.56 | 35.32 | 19.45 | 17.74 | 18.17 |
|
ROE (%)
|
19.78 | 77.18 | 10.72 | 26.54 | -21.14 |
|
ROA (%)
|
6.48 | 15.75 | 3.10 | 6.94 | -5.57 |
|
EBIT Margin (%)
|
18.85 | 49.24 | 0.21 | 25.26 | -4.91 |
|
Net Margin (%)
|
16.20 | 31.90 | 3.64 | 17.82 | -12.47 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Johnson & Johnson (JNJ) | Eli Lilly and Company (LLY) | Merck & Company Inc (MRK) | Novartis AG - ADR | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
7.80 | 45.51 | 4.79 | -0.12 | 6.54 |
|
EBIT Growth (%)
|
-41.80 | 70.32 | -99.40 | -18.88 | -113.96 |
|
Net Profit Growth (%)
|
-35.92 | 49.79 | -87.11 | -30.29 | -147.63 |
|
EPS Growth (%)
|
-36.38 | 50.65 | -87.04 | -28.45 | -148.77 |
|
Book Value Growth (%)
|
2.00 | 70.28 | -- | -14.48 | -39.33 |
Valuation Ratios
| Johnson & Johnson (JNJ) | Eli Lilly and Company (LLY) | Merck & Company Inc (MRK) | Novartis AG - ADR | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
18.83 | 46.76 | 14.35 | 18.92 | 18.07 |
|
Price / Book Value
|
6.19 | 36.37 | 4.98 | 5.77 | 6.77 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
12.97 | 31.56 | 10.54 | 12.68 | 12.45 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Johnson & Johnson (JNJ) | Eli Lilly and Company (LLY) | Merck & Company Inc (MRK) | Novartis AG - ADR | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.44 | 1.17 | 0.96 | 0.99 | 0.00 |
|
Short term debt to equity ratio
|
0.11 | 0.06 | 0.05 | 0.27 | 0.19 |
|
Current Ratio
|
1.02 | 1.39 | 1.54 | 0.88 | 1.38 |
|
Quick Ratio
|
0.74 | 1.00 | 1.30 | 0.70 | 1.22 |
|
Interest Coverage
|
23.23 | 30.52 | 4.37 | 9.02 | -1.51 |
Operating Efficiency Ratios
| Johnson & Johnson (JNJ) | Eli Lilly and Company (LLY) | Merck & Company Inc (MRK) | Novartis AG - ADR | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
19.11 | 29.18 | 0.00 | 17.69 | 16.16 |
|
Asset Turnover
|
0.40 | 0.49 | 0.85 | 0.39 | 0.45 |
|
Receivable days
|
70.00 | 93.67 | 64.57 | 63.79 | 57.89 |
|
Inventory Days
|
160.77 | 352.51 | 128.14 | 159.98 | 102.06 |
|
Payable days
|
134.61 | 142.23 | 85.14 | 120.44 | 45.35 |
|
Cash Conversion Cycle
|
96.16 | 303.95 | 107.57 | 103.33 | 114.61 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
